Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Expression of B7-H1, a costimulating glycoprotein in the B7 family, is normally restricted to macrophage-lineage cells, providing a potential costimulatory signal source for regulation of T cell activation. In contrast, aberrant expression of B7-H1 by tumor cells has been implicated in impairment of T cell function and survival, resulting in defective host antitumoral immunity. The relationship between tumor-associated B7-H1 and clinical cancer progression is unknown. Herein, we report B7-H1 expression by both renal cell carcinoma (RCC) tumors of the kidney and RCC tumor-infiltrating lymphocytes. In addition, our analysis of 196 clinical specimens reveals that patients harboring high intratumoral expression levels of B7-H1, contributed by tumor cells alone, lymphocytes alone, or tumor and/or lymphocytes combined, exhibit aggressive tumors and are at markedly increased risk of death from RCC. In fact, patients with high tumor and/or lymphocyte B7-H1 levels are 4.5 times more likely to die from their cancer than patients exhibiting low levels of B7-H1 expression (risk ratio 4.53; 95% confidence interval 1.94–10.56; P < 0.001.) Thus, our study suggests a previously undescribed mechanism whereby RCC may impair host immunity to foster tumor progression. B7-H1 may prove useful as a prognostic variable for RCC patients both pre- and posttreatment. In addition, B7-H1 may represent a promising target to facilitate more favorable responses in patients who require immunotherapy for treatment of advanced RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequent human studies have consistently shown that PD-L1 and PD-L2 expression not only increases in cancerous tissues but is also linked to poor disease prognosis in many cancer types (50)(51)(52)(53)(54)(55)(56).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Self-citationIwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Self-citationPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
The Heidelberg classification of renal cell tumours
Kovacs, G., Akhtar, M., Beckwith, B. J., Bugert, P., Cooper, C. S., Delahunt, B., Eble, J. N., Fleming, S., Ljungberg, B., Medeiros, L. J., et al. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199710)183:2<131::aid-path931>3.0.co;2-g · Cited by 1,354
FRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64153-5 · Cited by 1,175
Self-citationComparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma
Cheville, J. C., Lohse, C. M., Zincke, H., Weaver, A. L., & Blute, M. L. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200305000-00005 · Cited by 1,087
Self-citationHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMA
PANTUCK, A. J., ZISMAN, A., & BELLDEGRUN, A. S. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65640-6 · Cited by 882
Research works printed but not linked: 13
- Strome, S.-E., Dong, H., Tamura, H., Voss, S.-G., Flies, D.-B., Tamada, K., Salomao, D., Cheville, J.-C, Hirano, F., Lin, W., et al. (2003) Cancer Res. 63, 6501–6505. [PubMed] [Google Scholar]
- Graham, S., Babayan, R.-K., Lamm, D.-L., Sawczuk, I., Ross, S.-D., Lavin, P.-T., Osband, M.-E. & Krane, R.-J. (1993) Semin. Urol. 11, 27–34. [PubMed] [Google Scholar]
- Krejci, K.-G., Markiewicz, M.-A. & Kwon, E.-D. (2003) J. Urol. 171, 870–876. [DOI] [PubMed] [Google Scholar]
- Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H. & Ohtani, H. (2001) Cancer Res. 61, 5132–5136. [PubMed] [Google Scholar]
- Storkel, S., Eble, J.-N., Adlakha, K., Amin, M., Blute, M.-L., Bostwick, D.-G., Darson, M., Delahunt, B. & Iczkowski, K. (1997) Cancer 80, 987–989. [DOI] [PubMed] [Google Scholar]
- Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., Weller, M. & Wiendl, H. (2003) Cancer Res. 63, 7462–7467. [PubMed] [Google Scholar]
- Uzzo, R.-G., Rayman, P., Kolenko, V., Clark, P.-E., Bloom, T., Ward, A.-M., Molto, L., Tannenbaum, C., Worford, L.-J, Bukowski, R.-M., et al. (1999) Clin. Cancer Res. 5, 1219–1229. [PubMed] [Google Scholar]
- Alexander, J.-P., Kudoh, S., Melsop, K.-A., Hamilton, T.-A., Edinger, M.-G., Tubbs, R.-R., Sica, D., Tuason, L., Klein, E., Bukowski, R., et al. (1993) Cancer. Res. 53, 1380–1387. [PubMed] [Google Scholar]
- Li, X., Liu, J., Park, J.-K., Hamilton, T.-A., Rayman, P., Klein, E., Edinger, M., Tubbs, R., Bukowski, R. & Finke, J. (1994) Cancer Res. 54, 5424–5429. [PubMed] [Google Scholar]
- Kudoh, S., Redovan, C., Rayman, P., Edinger, M., Tubbs, R.-R., Novick, A., Finke, J.-H. & Bukowski, R.-M. (1997) J. Immunol. 20, 479–487. [DOI] [PubMed] [Google Scholar]
- Motzer, R.-J. (2003) Crit. Rev. Oncol. Hematol. 46S, s33–s39. [DOI] [PubMed] [Google Scholar]
- Hofmockel, G., Tsatalpas, P., Muller, H., Dammrich, J., Poot, M., Maurer-Schultze, B., Muller-Hermelink, H.-K., Frohmuller, H.-G. & Bassukas, I.-D. (1995) Cancer 76, 296–306. [DOI] [PubMed] [Google Scholar]
- Shimazui, T., Oosterwijk, E., Akaza, H., Bringuier, P., Ruijter, E., van Berkel, H., Wakka, J.-O., van Bokhoven, A., Debruyne, F.-M. & Schalken, J.-A. (1998) Clin. Cancer Res. 4, 2419–2424. [PubMed] [Google Scholar]
Cited by
Items 101–200 of 796
Checkpoint blocking antibodies in cancer immunotherapy
Kyi, C., & Postow, M. A. (2014) · FEBS Letters · doi:10.1016/j.febslet.2013.10.015 · Cited by 249
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
Gevensleben, H., Dietrich, D., Golletz, C., Steiner, S., Jung, M., Thiesler, T., Majores, M., Stein, J., Uhl, B., Müller, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2042 · Cited by 235
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2023) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 240
High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma
Lin, Y.-M., Sung, W.-W., Hsieh, M.-J., Tsai, S.-C., Lai, H.-W., Yang, S.-M., Shen, K.-H., Chen, M.-K., Lee, H., Yeh, K.-T., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142656 · Cited by 231
Mansfield, A. S., Roden, A. C., Peikert, T., Sheinin, Y. M., Harrington, S. M., Krco, C. J., Dong, H., & Kwon, E. D. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000177 · Cited by 238
“In renal cell carcinoma, the proportion of patients with B7-H1 expression has been higher in studies that use fresh-frozen tissue instead of formalin-fixed paraffin-embedded.(10,27,28) However, given the rarity of MPM and the often rather small amount of tissue that was needed for diagnostic purposes in its entirety,…”
BackgroundSelf-citationTowards individualized therapy for metastatic renal cell carcinoma
Kotecha, R. R., Motzer, R. J., & Voss, M. H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0209-1 · Cited by 234
Beckers, R. K., Selinger, C. I., Vilain, R., Madore, J., Wilmott, J. S., Harvey, K., Holliday, A., Cooper, C. L., Robbins, E., Gillett, D., et al. (2016) · Histopathology · doi:10.1111/his.12904 · Cited by 231
Tamura, H., Ishibashi, M., Yamashita, T., Tanosaki, S., Okuyama, N., Kondo, A., Hyodo, H., Shinya, E., Takahashi, H., Dong, H., et al. (2013) · Leukemia · doi:10.1038/leu.2012.213 · Cited by 225
Self-citationThompson, R. H., Dong, H., & Kwon, E. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1868 · Cited by 228
Self-citationCedrés, S., Ponce-Aix, S., Zugazagoitia, J., Sansano, I., Enguita, A., Navarro-Mendivil, A., Martinez-Marti, A., Martinez, P., & Felip, E. (2015) · PLOS ONE · doi:10.1371/journal.pone.0121071 · Cited by 219
Overall survival and PD‐L1 expression in metastasized malignant melanoma
Gadiot, J., Hooijkaas, A. I., Kaiser, A. D. M., van Tinteren, H., van Boven, H., & Blank, C. (2011) · Cancer · doi:10.1002/cncr.25747 · Cited by 221
Chen, Y.-B., Mu, C.-Y., & Huang, J.-A. (2012) · Tumori Journal · doi:10.1177/030089161209800612 · Cited by 218
Ghebeh, H., Barhoush, E., Tulbah, A., Elkum, N., Al-Tweigeri, T., & Dermime, S. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-57 · Cited by 211
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
Georgiou, K., Chen, L., Berglund, M., Ren, W., de Miranda, N. F. C. C., Lisboa, S., Fangazio, M., Zhu, S., Hou, Y., Wu, K., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686550 · Cited by 199
Self-citationKondo, A., Yamashita, T., Tamura, H., Zhao, W., Tsuji, T., Shimizu, M., Shinya, E., Takahashi, H., Tamada, K., Chen, L., et al. (2010) · Blood · doi:10.1182/blood-2009-12-255125 · Cited by 201
Self-citationLiu, X.-D., Hoang, A., Zhou, L., Kalra, S., Yetil, A., Sun, M., Ding, Z., Zhang, X., Bai, S., German, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0244 · Cited by 204
Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
Swaika, A., Hammond, W. A., & Joseph, R. W. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.02.009 · Cited by 201
Role of PD-1 in Immunity and Diseases
Chamoto, K., Al-Habsi, M., & Honjo, T. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_67 · Cited by 200
Pentcheva‐Hoang, T., Corse, E., & Allison, J. P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00763.x · Cited by 203
Yang, J., & Hu, L. (2019) · Medicinal Research Reviews · doi:10.1002/med.21530 · Cited by 190
Tumor immunoediting and immunosculpting pathways to cancer progression
Reiman, J. M., Kmieciak, M., Manjili, M. H., & Knutson, K. L. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.009 · Cited by 199
Tumor-Infiltrating Foxp3−CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma
Siddiqui, S. A., Frigola, X., Bonne-Annee, S., Mercader, M., Kuntz, S. M., Krambeck, A. E., Sengupta, S., Dong, H., Cheville, J. C., Lohse, C. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2139 · Cited by 202
Self-citationChowdhury, P. S., Chamoto, K., & Honjo, T. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12708 · Cited by 191
Yu, W., Hua, Y., Qiu, H., Hao, J., Zou, K., Li, Z., Hu, S., Guo, P., Chen, M., Sui, S., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2701-z · Cited by 179
Programmed Cell Death Ligand 1 Expression in Osteosarcoma
Shen, J. K., Cote, G. M., Choy, E., Yang, P., Harmon, D., Schwab, J., Nielsen, G. P., Chebib, I., Ferrone, S., Wang, X., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0224 · Cited by 193
“Several previous studies have demonstrated conflicting results varying from positive correlation of tumor aggressiveness in renal cell carcinoma (33, 36), to observing no correlation with clinicopathologic variables (24), to an inverse relationship in which high PDL1 expression was associated with increased survival i…”
The New B7s: Playing a Pivotal Role in Tumor Immunity
Flies, D. B., & Chen, L. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31802e085a · Cited by 189
Self-citationThe role of PD-L1 in the radiation response and clinical outcome for bladder cancer
Wu, C.-T., Chen, W.-C., Chang, Y.-H., Lin, W.-Y., & Chen, M.-F. (2016) · Scientific Reports · doi:10.1038/srep19740 · Cited by 191
Bhindi, B., Abel, E. J., Albiges, L., Bensalah, K., Boorjian, S. A., Daneshmand, S., Karam, J. A., Mason, R. J., Powles, T., & Bex, A. (2019) · European Urology · doi:10.1016/j.eururo.2018.09.016 · Cited by 176
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis
Iacovelli, R., Nolè, F., Verri, E., Renne, G., Paglino, C., Santoni, M., Cossu Rocca, M., Giglione, P., Aurilio, G., Cullurà, D., et al. (2016) · Targeted Oncology · doi:10.1007/s11523-015-0392-7 · Cited by 178
Ishii, H., Azuma, K., Kawahara, A., Yamada, K., Imamura, Y., Tokito, T., Kinoshita, T., Kage, M., & Hoshino, T. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000414 · Cited by 177
Okuma, Y., Hosomi, Y., Nakahara, Y., Watanabe, K., Sagawa, Y., & Homma, S. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2016.11.023 · Cited by 176
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
Eun, Y., Kim, I. Y., Sun, J.-M., Lee, J., Cha, H.-S., Koh, E.-M., Kim, H., & Lee, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50574-6 · Cited by 171
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
Crane, C. A., Panner, A., Murray, J. C., Wilson, S. P., Xu, H., Chen, L., Simko, J. P., Waldman, F. M., Pieper, R. O., & Parsa, A. T. (2009) · Oncogene · doi:10.1038/onc.2008.384 · Cited by 181
“…28, 306–312 & 2009 Macmillan Publishers Limited All rights reserved 0950-9232/09 $32.00 www.nature.com/onc that immunoresistance confounds conventional therapies (Thompson et al., 2004, 2006, 2007; Inman et al., 2007; Krambeck et al., 2007; Geng et al., 2008; Loos et al., 2008; Routh et al., 2008).”
BackgroundInfluentialSelf-citationUpregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer
Qing, Y., Li, Q., Ren, T., Xia, W., Peng, Y., Liu, G. L., Luo, H., Yang, Y., Dai, X. Y., Zhou, S.-F., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s75152 · Cited by 179
Shin, S.-J., Jeon, Y. K., Kim, P.-J., Cho, Y. M., Koh, J., Chung, D. H., & Go, H. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4903-7 · Cited by 180
Shi, S.-J., Wang, L.-J., Wang, G.-D., Guo, Z.-Y., Wei, M., Meng, Y.-L., Yang, A.-G., & Wen, W.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076012 · Cited by 178
Majzner, R. G., Simon, J. S., Grosso, J. F., Martinez, D., Pawel, B. R., Santi, M., Merchant, M. S., Geoerger, B., Hezam, I., Marty, V., et al. (2017) · Cancer · doi:10.1002/cncr.30724 · Cited by 179
Palsson-McDermott, E. M., Dyck, L., Zasłona, Z., Menon, D., McGettrick, A. F., Mills, K. H. G., & O’Neill, L. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01300 · Cited by 173
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Sato, H., Okonogi, N., & Nakano, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01666-1 · Cited by 173
Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinoma
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Chen, L., Zincke, H., Blute, M. L., Leibovich, B. C., et al. (2005) · Cancer · doi:10.1002/cncr.21470 · Cited by 174
“We previously reported that patients with high aggregate B7-H1 in primary RCC were at significant risk of death, although statistical significance was not maintained after adjusting for the Mayo Clinic SSIGN score.(12) The SSIGN score is a composite index developed specifically for patients with clear cell RCC utilizi…”
BackgroundMethodSelf-citationNovel Approaches to Improve the Efficacy of Immuno-Radiotherapy
Shevtsov, M., Sato, H., Multhoff, G., & Shibata, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00156 · Cited by 173
Merelli, B., Massi, D., Cattaneo, L., & Mandalà, M. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.002 · Cited by 170
Zhu, J., Chen, L., Zou, L., Yang, P., Wu, R., Mao, Y., Zhou, H., Li, R., Wang, K., Wang, W., et al. (2014) · Human Immunology · doi:10.1016/j.humimm.2014.01.006 · Cited by 171
Self-citationPeptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy
Li, C., Zhang, N., Zhou, J., Ding, C., Jin, Y., Cui, X., Pu, K., & Zhu, Y. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0035 · Cited by 161
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites
Perng, P., & Lim, M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00153 · Cited by 166
Ghebeh, H., Tulbah, A. M., Mohammed, S. F., Elkum, N. B., Amer, S. M. B., Al‐Tweigeri, T., & Dermime, S. (2007) · International Journal of Cancer · doi:10.1002/ijc.22703 · Cited by 174
miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity
Jia, L., Xi, Q., Wang, H., Zhang, Z., Liu, H., Cheng, Y., Guo, X., Zhang, J., Zhang, Q., Zhang, L., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.074 · Cited by 159
Singer, K., Kastenberger, M., Gottfried, E., Hammerschmied, C. G., Büttner, M., Aigner, M., Seliger, B., Walter, B., Schlösser, H., Hartmann, A., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25543 · Cited by 160
“Possible mechanisms are defects in the antigen processing machinery(32,33) or increased expression of inhibitory molecules on tumor cells.(34) As several studies have demonstrated that upregulation of LDHA and GLUT-1 is related to a more aggressive phenotype and poor prognosis the aim of our study was to investigate a…”
BackgroundMcDermott, D. F., Cheng, S.-C., Signoretti, S., Margolin, K. A., Clark, J. I., Sosman, J. A., Dutcher, J. P., Logan, T. F., Curti, B. D., Ernstoff, M. S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1520 · Cited by 156
Self-citationImmune checkpoint inhibition in ovarian cancer
Hamanishi, J., Mandai, M., & Konishi, I. (2016) · International Immunology · doi:10.1093/intimm/dxw020 · Cited by 154
Proto, C., Ferrara, R., Signorelli, D., Russo, G. L., Galli, G., Imbimbo, M., Prelaj, A., Zilembo, N., Ganzinelli, M., Pallavicini, L. M., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.03.004 · Cited by 164
Balan, M., Mier y Teran, E., Waaga-Gasser, A. M., Gasser, M., Choueiri, T. K., Freeman, G., & Pal, S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612689 · Cited by 155
Jilaveanu, L. B., Shuch, B., Zito, C. R., Parisi, F., Barr, M., Kluger, Y., Chen, L., & Kluger, H. M. (2014) · Journal of Cancer · doi:10.7150/jca.8167 · Cited by 158
Self-citationImmune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy
Lee, L., Gupta, M., & Sahasranaman, S. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.591 · Cited by 148
Wang, W., Li, F., Mao, Y., Zhou, H., Sun, J., Li, R., Liu, C., Chen, W., Hua, D., & Zhang, X. (2013) · Human Genetics · doi:10.1007/s00439-013-1275-6 · Cited by 154
Sau, S., Alsaab, H. O., Bhise, K., Alzhrani, R., Nabil, G., & Iyer, A. K. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.028 · Cited by 150
Xylinas, E. N., Robinson, B. D., Kluth, L. A., Volkmer, B. G., Hautmann, R. E., Küfer, R., Zerbib, M., Kwon, E. D., Thompson, R. H., Boorjian, S. A., et al. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.08.023 · Cited by 155
Self-citationXu, J. X., Maher, V. E., Zhang, L., Tang, S. W., Sridhara, R., Ibrahim, A., Kim, G., & Pazdur, R. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0476 · Cited by 156
PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation
Qiu, X. Y., Hu, D. X., Chen, W., Chen, R. Q., Shi, Q., Li, C. Y., Li, Y. J., Xiong, X., Liu, D., Pan, F., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.002 · Cited by 162
Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer
Loos, M., Giese, N. A., Kleeff, J. H., Giese, T., Gaida, M. M., Bergmann, F., Laschinger, M., Büchler, M. W., & Frieß, H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.056 · Cited by 160
Massi, D., Brusa, D., Merelli, B., Ciano, M., Audrito, V., Serra, S., Buonincontri, R., Baroni, G., Nassini, R., Minocci, D., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu452 · Cited by 152
Melanoma Cells Express ICOS Ligand to Promote the Activation and Expansion of T-Regulatory Cells
Martin-Orozco, N., Li, Y., Wang, Y., Liu, S., Hwu, P., Liu, Y.-J., Dong, C., & Radvanyi, L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1379 · Cited by 142
Clinical and biological significance of circulating tumor cells in cancer
Masuda, T., Hayashi, N., Iguchi, T., Ito, S., Eguchi, H., & Mimori, K. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.01.010 · Cited by 144
Ock, C.-Y., Kim, S., Keam, B., Kim, M., Kim, T. M., Kim, J.-H., Jeon, Y. K., Lee, J.-S., Kwon, S. K., Hah, J. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7431 · Cited by 144
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino, L., Botti, G., Lorigan, P. C., Masucci, G. V., Hipp, J., Horak, C. E., Melero, I., & Ascierto, P. A. (2016) · Drugs · doi:10.1007/s40265-016-0588-x · Cited by 153
Li, Y., Li, F., Jiang, F., Lv, X., Zhang, R., Lü, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071151 · Cited by 182
Atkins, M. B., Clark, J. I., & Quinn, D. I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx151 · Cited by 156
B7–H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis
Arigami, T., Narita, N., Mizuno, R., Nguyen, L., Ye, X., Chung, A., Giuliano, A. E., & Hoon, D. S. B. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181f1939d · Cited by 146
Mkrtichyan, M., Najjar, Y. G., Raulfs, E. C., Abdalla, M. Y., Samara, R., Rotem‐Yehudar, R., Cook, L., & Khleif, S. N. (2011) · European Journal of Immunology · doi:10.1002/eji.201141639 · Cited by 144
Soluble B7-H1: Differences in production between dendritic cells and T cells
Frigola, X., Inman, B. A., Krco, C. J., Liu, X., Harrington, S. M., Bulur, P. A., Dietz, A. B., Dong, H., & Kwon, E. D. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.11.001 · Cited by 146
Self-citationCancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03912.x · Cited by 141
PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
Dolan, D. E., & Gupta, S. (2014) · Cancer Control · doi:10.1177/107327481402100308 · Cited by 145
Yamamoto, R., Nishikori, M., Tashima, M., Sakai, T., Ichinohe, T., Takaori‐Kondo, A., Ohmori, K., & Uchiyama, T. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01302.x · Cited by 147
Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients
Piersma, S. J. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0066-7 · Cited by 150
Lian, S., Xie, R., Ye, Y., Xie, X., Li, S., Lu, Y., Li, B., Cheng, Y., Katanaev, V. L., & Jia, L. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.018 · Cited by 142
Yu, H., Batenchuk, C., Badzio, A., Boyle, T. A., Czapiewski, P., Chan, D. C., Lu, X., Gao, D., Ellison, K., Kowalewski, A. A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.002 · Cited by 135
Xing, K., Gu, B., Zhang, P., & Wu, X. (2015) · BMC Immunology · doi:10.1186/s12865-015-0103-2 · Cited by 146
Harnessing the immune system to treat cancer
Bhardwaj, N. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32136 · Cited by 152
Immunotherapy earns its spot in the ranks of cancer therapy
Pardoll, D. M., & Drake, C. G. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112275 · Cited by 147
Genetics and epigenetics of renal cell cancer
Baldewijns, M. M. L. L., van Vlodrop, I. J. H., Schouten, L. J., Soetekouw, P. M. M. B., de Bruïne, A. P., & van Engeland, M. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.12.002 · Cited by 146
Baksh, K. A., & Weber, J. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.015 · Cited by 146
Obeid, J. M., Erdag, G., Smolkin, M. E., Deacon, D. H., Patterson, J. W., Chen, L., Bullock, T. N., & Slingluff, C. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1235107 · Cited by 129
Self-citationMaine, C. J., Aziz, N. H. A., Chatterjee, J., Hayford, C., Brewig, N., Whilding, L. M., George, A. J. T., & Ghaem‐Maghami, S. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1503-x · Cited by 136
Bilen, M. A., Shabto, J. M., Martini, D. J., Liu, Y., Lewis, C. M., Collins, H., Akce, M., Kissick, H. T., Carthon, B. C., Shaib, W. L., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6073-7 · Cited by 132
Ukpo, O. C., Thorstad, W. L., & Lewis, J. S. (2012) · Head and Neck Pathology · doi:10.1007/s12105-012-0406-z · Cited by 131
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters
Ebelt, K., Babaryka, G., Frankenberger, B., Stief, C. G., Eisenmenger, W., Kirchner, T., Schendel, D. J., & Noeßner, E. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.02.015 · Cited by 133
Wu, X., Zhang, H.-B., Xing, Q. R., Cui, J., Li, J., Li, Y., Tan, Y. Q., & Wang, S. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.416 · Cited by 138
Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion
Liu, X., Liu, L., Ren, Z., Yang, K., Xu, H., Luan, Y., Fu, K., Guo, J., Peng, H., Zhu, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.062 · Cited by 126
Coombs, M. R. P., Harrison, M. E., & Hoskin, D. W. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.023 · Cited by 126
Bertucci, F., Finetti, P., Colpaert, C., Mamessier, É., Parizel, M., Dirix, L. Y., Viens, P., Birnbaum, D., & Laere, S. V. (2015) · Oncotarget · doi:10.18632/oncotarget.3642 · Cited by 137
Mahoney, K. M., Sun, H. H., Liao, X., Hua, P., Callea, M., Greenfield, E. A., Hodi, F. S., Sharpe, A. H., Signoretti, S., Rodig, S. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0116 · Cited by 133
Hoffmann, N. E., Sheinin, Y. M., Lohse, C. M., Parker, A. S., Leibovich, B. C., Jiang, Z., & Kwon, E. D. (2008) · Cancer · doi:10.1002/cncr.23296 · Cited by 129
Self-citationCampbell, S. C., & Lane, B. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00049-9 · Cited by 132
Role of PD-L1 and PD-L2 in allergic diseases and asthma
Singh, A. K., Stock, P., & Akbari, O. (2010) · Allergy · doi:10.1111/j.1398-9995.2010.02458.x · Cited by 128
B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression
Geng, L., Huang, D., Liu, J., Qian, Y., Deng, J., Li, D., Hu, Z., Zhang, J., Jiang, G., & Zheng, S. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0364-8 · Cited by 129
Sun, W. Y., Lee, Y. K., & Koo, J. S. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0925-6 · Cited by 130
Duchnowska, R., Pęksa, R., Radecka, B. S., Mandat, T. S., Trojanowski, T., Jarosz, B., Czartoryska-Arłukowicz, B., Olszewski, W. P., Och, W., Kalinka‐Warzocha, E., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0702-8 · Cited by 124
Recent advances in the clinical development of immune checkpoint blockade therapy
Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 114
B7‐H3 and Its Role in Antitumor Immunity
Loos, M., Hedderich, D. M., Friess, H., & Kleeff, J. H. (2010) · Journal of Immunology Research · doi:10.1155/2010/683875 · Cited by 123
Metadata
- Authors
- Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., Zincke, H., Blute, M. L., Strome, S. E., Leibovich, B. C., & Kwon, E. D.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-11-29
- Volume
- 101
- Issue
- 49
- Pages
- 17174-17179
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC534606
- OpenAlex
- W4230861071
- Cited by
- 776
- References
- 48
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 15 · 2023: 29 · 2022: 32 · 2021: 42 · 2020: 51 · 2019: 60 · 2018: 57 · 2017: 76 · 2016: 65 · 2015: 69 · 2014: 57 · 2013: 29 · 2012: 28
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, renal cell carcinoma, tumor-infiltrating lymphocytes, tumor progression, prognostic factors, tumor immune evasion, T cell costimulation, immunotherapy targets, cancer mortality
- MeSH terms
- Carcinoma, Renal Cell, Follow-Up Studies, Humans, Immunity, Immunohistochemistry, Membrane Glycoproteins, Neoplasm Proteins, Peptides, Prognosis, Antigens, CD, Odds Ratio, Survival Analysis, Lymphocytes, Tumor-Infiltrating, B7-1 Antigen, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.